Cargando…

Are we closer to having drugs to treat muscle wasting disease?

The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise trai...

Descripción completa

Detalles Bibliográficos
Autores principales: Morley, John E., von Haehling, Stephan, Anker, Stefan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053564/
https://www.ncbi.nlm.nih.gov/pubmed/24865381
http://dx.doi.org/10.1007/s13539-014-0149-7
_version_ 1782320392932687872
author Morley, John E.
von Haehling, Stephan
Anker, Stefan D.
author_facet Morley, John E.
von Haehling, Stephan
Anker, Stefan D.
author_sort Morley, John E.
collection PubMed
description The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors.
format Online
Article
Text
id pubmed-4053564
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-40535642014-06-12 Are we closer to having drugs to treat muscle wasting disease? Morley, John E. von Haehling, Stephan Anker, Stefan D. J Cachexia Sarcopenia Muscle Editorial The two most common muscle wasting diseases in adults are sarcopenia and cachexia. Despite differences in their pathophysiology, it is believed that both conditions are likely to respond to drugs that increase muscle mass and muscle strength. The current gold standard in this regard is exercise training. This article provides an overview of candidate drugs to treat muscle wasting disease that are available or in development. Drugs highlighted here include ghrelin agonists, selective androgen receptor molecules, megestrol acetate, activin receptor antagonists, espindolol, and fast skeletal muscle troponin inhibitors. Springer Berlin Heidelberg 2014-05-28 2014-06 /pmc/articles/PMC4053564/ /pubmed/24865381 http://dx.doi.org/10.1007/s13539-014-0149-7 Text en © Springer-Verlag Berlin Heidelberg 2014
spellingShingle Editorial
Morley, John E.
von Haehling, Stephan
Anker, Stefan D.
Are we closer to having drugs to treat muscle wasting disease?
title Are we closer to having drugs to treat muscle wasting disease?
title_full Are we closer to having drugs to treat muscle wasting disease?
title_fullStr Are we closer to having drugs to treat muscle wasting disease?
title_full_unstemmed Are we closer to having drugs to treat muscle wasting disease?
title_short Are we closer to having drugs to treat muscle wasting disease?
title_sort are we closer to having drugs to treat muscle wasting disease?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053564/
https://www.ncbi.nlm.nih.gov/pubmed/24865381
http://dx.doi.org/10.1007/s13539-014-0149-7
work_keys_str_mv AT morleyjohne areweclosertohavingdrugstotreatmusclewastingdisease
AT vonhaehlingstephan areweclosertohavingdrugstotreatmusclewastingdisease
AT ankerstefand areweclosertohavingdrugstotreatmusclewastingdisease